{
    "nct_id": "NCT04221477",
    "official_title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)",
    "inclusion_criteria": "* Diagnosis of active or active/chronic ISN/RPS 2003 Class III or IV proliferative LN as evidenced by renal biopsy performed within 6 months. Participants may co-exhibit Class V disease in addition to either Class III or Class IV disease\n* Urine protein to creatinine ratio greater than or equal to (>/=) 1 on a 24-hour collection\n* Other inclusion criteria may apply\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Pregnancy or breastfeeding\n* Severe renal impairment or the need for dialysis or renal transplantation\n* Receipt of an excluded therapy, including any anti-CD20 therapy less than 9 months prior to screening or during screening; or cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening\n* Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude patient participation\n* Known active infection of any kind or recent major episode of infection\n* Intolerance or contraindication to study therapies\n* Other exclusion criteria may apply",
    "miscellaneous_criteria": "Key"
}